Overview

High-Dose Cephalexin for Cellulitis: A Randomized Controlled Trial

Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Cellulitis is a common condition diagnosed and managed in the ED that carries significant burden on healthcare systems globally. Cellulitis is the 8th most common reason patients present to an ED in Canada. Among middle-aged patients (45-64 years) it is the 5th most common reason to visit an ED. This disease is responsible for significant healthcare system burden due to high hospitalization rates and subsequent costs. We conducted a health records review at two large urban EDs in Ottawa, and found that 29.6% of patients with cellulitis are admitted to hospital. In a separate study, we found that the mean cost of care to hospitalize cellulitis patients for IV antibiotics was $10,145 CDN.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Network of Canadian Emergency Researchers (NCER)
The Ottawa Hospital Academic Medical Association
Treatments:
Cephalexin